Dacomitinib

达可替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameDacomitinib
Drug Alias Name达克替尼Dacomitinibum达米替尼VizimproPF-00299804-03 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR 19del inhibitorsEGFR L858R inhibitorsEpidermal growth factor receptor erbB1 inhibitors +[5] 
TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2 +[5] 
Therapy Area/IndicationsSolid tumoursLiver DiseasesNeoplasm Metastasis +[18] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2018/09/27
Country/TerritoryBelgiumCanadaUnited States +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Manufacturing Deutschland GmbhPfizer Europe Ma Eeig +[4] 
Inactive CompaniesYonsei UniversityNational Cancer InstituteUniversity Health Network (Uhn)
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursLiver DiseasesNeoplasm Metastasis +[17] 

Other Information

ATC CodeL01EB07
Related LinksWikipediaKEGG